Aussie health start-up Eucalyptus, a telehealth weight-loss unicorn, has been acquired by a US giant for a staggering $1.6 billion. This deal has made its Sydney founder, Tim Doyle, $163 million richer. But here's where it gets controversial: some argue that the acquisition undervalues the company's potential, while others believe it's a testament to its success. And this is the part most people miss: the deal has sparked a debate about the future of healthcare innovation in Australia. Will this sale lead to a decline in local health tech startups, or will it inspire more investment and growth? Join the conversation and share your thoughts in the comments. Who do you think will benefit the most from this acquisition? And what does it mean for the future of healthcare in Australia?
